WEBSTER FINANCIAL CORPORATION (WBS): what the price requires

At today's price, WEBSTER FINANCIAL CORPORATION (WBS) is priced for 14.1% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/WBS

Headline

FieldValue
TickerWBS
CompanyWEBSTER FINANCIAL CORPORATION
Current price$76.24/sh
CompositionCommercial Banking 50% / Healthcare Financial Services 18% / Consumer Banking 33%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Price-to-book1.29x
Return on equity now10.4%

The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The price sits beyond a 12.4% return on equity sustained for 40 years and is not resolvable as a sustainable-ROE point. The rarity read below is the honest signal.

Solve inputs: computed at a 11.9% cost of equity; ROE searched up to the 12.4% ROE ceiling.

Reconcile: at the x-ray's 9.3% required return this reads ~10.8%; the models below use their own rates.

How unusual the bet is: extreme

ReferenceValue
vs own history+1.85σ
cohort percentile (of 119 peers)43
sustained it ~10 years at this level63%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.03x3expensive
Earnings0.77x2justifies
Relative0.36x3justifies
Growth1.13x1expensive

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$50.281.52xyesTBVPS $39.89 × 1.26x (ROE (TTM) 10.7% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 1.30% allowance/loans → ×0.94)
Relative ValuationRelative$70.401.08xyesP/E 10x (static sector reference · 2026-04), scenarios: 8.3x / 10.0x / 11.7x (bear / base = reference held flat / bull), EV/EBITDA N/Ax
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$69.131.10xyesBV/sh $59.89, ROE (TTM) 10.7%, ke 9.3%
Two-Stage Excess ReturnAsset$74.081.03xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$67.201.13xyesRev $2.9B, growth 10% (input: historical growth; tapered), Terminal P/S: 3.4x / 4.2x / 4.9x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$213.500.36xyesEPS $6.10, growth 35% (input: historical EPS growth), PEG=0.34 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$90.660.84xyes√(22.5 × EPS $6.10 × BVPS $59.89) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$196.830.39xyesEPS $6.10 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$228.750.33xyesEPS $6.10 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$65.951.16xyesEPS $6.10 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (dilution)2.0%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Banks in this band are valued not on what they earn this year but on the return they can hold on the capital they keep, and that is where Webster reads differently from the typical regional. The company carries a healthcare financial services business that pools $10.4 billion of deposits and administers another $6.5 billion of investment balances through linked accounts that never touch the balance sheet, with deposits there up to $10.4 billion at year-end 2025 from $9.97 billion the year before. Health savings money is among the stickiest deposit funding in banking. It comes in at low cost, it compounds with the account holders' own contributions, and it does not chase rate the way commercial operating cash does. That funding edge is the structural reason Webster could hold its net interest margin at 3.36% in the first quarter of 2026 while the cost of its interest-bearing liabilities was falling 18 basis points and the yield on earning assets fell 26.

The operating numbers underneath the funding are clean. First-quarter net income to common was $239.3 million, or $1.50 per diluted share, up from $1.30 a year earlier, on total revenue of $735.9 million split between $634.4 million of net interest income and $101.5 million of fee income. The efficiency ratio of 46.83% means it costs Webster under forty-seven cents to produce a dollar of revenue, and credit held: net charge-offs ran 0.29% of average loans and non-performing loans 0.91% of the total. The 10-K shows the loan book growing into the strength, with a $3.2 billion increase driven by commercial real estate, middle market, and sponsor and specialty finance origination. A return on equity near 10.7% on a trailing basis is solid bank profitability, not spectacular, and the price reflects that rather than betting on a leap.

The near-term return for a holder, though, is no longer about Webster compounding on its own. Banco Santander has agreed to acquire the company for $48.75 in cash and 2.0548 Santander American Depositary Shares per share, a roughly $12.3 billion transaction meant to lift Santander into the top tier of U.S. retail and commercial banking. The Office of the Comptroller of the Currency approved the bank merger on June 12, Webster shareholders have already voted yes, and what remains is the Federal Reserve Board and the European Central Bank, with a close targeted for the second half of 2026. For a holder, the bull case is that a regulated cash-and-stock takeover by a buyer that has already cleared its primary U.S. regulator carries a different risk profile than an open-ended operating thesis: the cash leg is fixed, and the remaining approvals are procedural gates with a named buyer behind them.

Bear Case

The advantage that made Webster distinctive is also the advantage a buyer now absorbs, and that reframes where the risk sits. For a standalone holder the question would be whether the healthcare-deposit moat keeps widening; for today's holder the question is whether a pending acquisition closes on the terms struck. Those are not the same risk, and the second one does not improve with good quarterly execution.

Start with what the price already embeds about the underlying bank. At roughly 1.3 times book the market is paying for a return on equity that sits above what Webster has lately delivered, against a trailing return near 10.7% and a longer-run average closer to 8%. The methods that lean on demonstrated earnings and on peer multiples already find the price full to slightly cheap, and only the forward-growth lens reaches well past it. That tells you the standalone equity is priced for steady, not accelerating, profitability. If the deal were to fall away and Webster reverted to trading on its own ROE, the support under the price would be the value-oriented methods near today's level, not a growth re-rating, and the stock would be exposed to whatever happens to bank multiples and credit through the cycle.

Then there is the deal itself, which is where the concentrated risk lives. The transaction still needs the Federal Reserve Board and, because the acquirer is a Spanish institution, the European Central Bank. Cross-border bank acquisitions draw scrutiny on both sides of the Atlantic, and a delay pushes the close and compresses the annualized return on the cash portion. The stock half of the consideration, 2.0548 Santander ADS per Webster share, is not fixed in dollars: it floats with Santander's own share price, so a Webster holder is exposed to the acquirer's stock between signing and close without the protection of a fixed exchange value. The clean efficiency ratio and the steady margin are real, but they are no longer the variables that decide a holder's outcome from here.

Valuation

Read a bank's price off the return it earns on its book, not off an operating multiple, and Webster's reading is unusually consistent across the methods that matter. At today's price the market pays about 1.3 times book value, which embeds a return on equity above the steady-state range the company has been earning, near 10.7% on a trailing basis and closer to 8% averaged over a longer window. The tangible book value per share is $39.89 and the book value per share $59.89, so the premium to book is modest by the standards of a profitable franchise bank.

The families of method line up the way a value-supported name does rather than a growth bet. The asset-value lens, built off book value and the spread of return over the cost of equity, lands right around the price; the simple excess-return method reaches $69.13 and its two-stage version $74.08 (June 28, 2026), both essentially at today's level. Peer multiples are the cheap read: applying a sector-median ten-times earnings, the relative valuation method lands at $71.40, with the price sitting only modestly above it. The dedicated bank model that prices tangible book at 1.26 times for a return-over-cost-of-equity spread comes in lower, at $50.28, reflecting a 1.30% allowance-to-loans credit haircut. Only the forward-growth method finds the price expensive, and that is the one lens that requires the bank to compound faster than it has. The pattern is the opposite of a momentum stock: most of the value methods support the price, and the demanding one is the speculative one.

The ordinary solvency questions a non-bank faces do not apply here. Webster's debt is deposit and wholesale funding, not corporate leverage, and the right frame is regulatory capital and the capacity to return it, not net debt or interest coverage. First-quarter credit metrics, charge-offs of 0.29% and non-performing loans of 0.91%, point to a balance sheet carrying the loan book comfortably. None of this resolves into a target, and it does not need to. The dominant price input now is the agreed Santander consideration of $48.75 in cash plus 2.0548 Santander ADS, which sets a floor under the cash leg and ties the rest to the acquirer's stock until the deal closes; the standalone methods describe the bank a buyer is paying to absorb.

Catalysts

The single catalyst that overshadows everything else is the Banco Santander acquisition. Santander agreed to buy Webster for $48.75 in cash and 2.0548 Santander American Depositary Shares per common share, a roughly $12.3 billion deal intended to push Santander into the top ten of U.S. retail and commercial banks. The Office of the Comptroller of the Currency approved the bank merger on June 12, a meaningful clearance because the OCC is the primary regulator of the combined national bank. Webster shareholders have already approved the transaction. The remaining gates are the Federal Reserve Board and, because the acquirer is Spanish, the European Central Bank, with a close expected in the second half of 2026.

Because of the pending deal, Webster has stopped holding earnings calls and no longer issues a forward financial outlook, so the usual guidance catalysts are gone. The events that move the stock from here are the two remaining regulatory decisions and the price of Santander's own ADS, which determines the value of the stock half of the consideration. First-quarter results were strong on their own terms, with GAAP EPS of $1.50 beating the prior year and net interest margin holding at 3.36%, but operating performance is now a secondary input to a holder's return relative to deal timing and the acquirer's share price.

Peer Cohorts (Per Segment, With Filing Citations)

Commercial Banking (reported)

Healthcare Financial Services (reported)

Consumer Banking (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

FY2025 10-K, accession 0000801337-26-000008 · Q1 2026 earnings release · company merger communications, June 2026 · OCC approval, June 12, 2026

View the full interactive WBS report on boothcheck